adesso (ADN1) H2 2023 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2023 earnings summary
31 Oct, 2026Executive summary
FY 2023 sales rose 26% to €1,135.9m, with 24 percentage points of organic growth and 2 points from acquisitions.
Earnings weakened: EBITDA fell 14% to €80.0m and EPS declined 89% to €0.49, amid low utilisation, project impairments and higher personnel costs.
Financial highlights
Gross profit increased 27% to €973.3m; personnel costs rose 32% to €773.2m and other operating expenses rose 25% to €135.3m.
EBT fell 71% to €12.2m; consolidated earnings dropped 88% to €3.4m, with income taxes of €8.8m and a 72% tax quota.
Operating cash flow doubled to €76.9m from €36.1m, and Free Cash Flow II was positive at €14.2m.
Outlook and guidance
FY 2024 sales guidance is >€1,250m, with expected double-digit growth; EBITDA guidance is €110m–€130m.
Margin is expected to improve, particularly in HY2; outlook cites strong IT Services demand and one additional working day.
Priorities include ramping offshore delivery in India, launching Managed Services, improving core IT Services utilisation, raising daily rates and reinforcing cash-flow focus.
Latest events from adesso
- Nine-month EBITDA rose 26% as sales grew 13%; FY guidance remains within reach.ADN1
Q3 2026 - 13% revenue and 21% EBITDA growth in H1 2026; guidance and AI expansion reaffirmed.ADN1
Q2 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 2025 - Sales and EBITDA grew 12% and 34% in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 2025 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU - Sales up 16% to €631.1m, but negative EPS and EBITDA guidance cut amid margin pressure.ADN1
H1 2024 - Sales up 11% in Q1 2025; margin recovery and stronger H2 earnings expected.ADN1
Q1 2025 TU - 14% sales growth and margin gains in 2024 set the stage for further expansion in 2025.ADN1
H2 2024